Tag
Sun Pharmaceutical Industries Limited
4 articles
Sun Pharma Schedules November 2026 Investor Meetings
Sun Pharma intimates schedule of three analyst/investor meetings in Mumbai on November 17-18, 2026.
Meetings include group and one-on-one sessions at CITIC-CLSA, Avendus Spark, and JM Financial confer
Sun Pharma Q2 FY27 Net Profit at ₹19.9 Billion
Sun Pharma reported Q2 FY27 sales of ₹161,000 million, an 11.8% YoY growth, with an EBITDA of ₹47,439 million.
The US business declined 8.2% YoY due to lenalidomide erosion, while the India formulatio
Sun Pharma Clarifies Assam Plant Quality Issue Report
Sun Pharma responds to stock exchanges regarding news report about production halt at Assam facility due to quality lapses.
Clarifies that the reported events occurred in August 2026 and were assessed
Sun Pharma Shareholders Approve Promoter Group Reclassification
Sun Pharma shareholders approved reclassification of certain persons from Promoter Group to Public category on 26 September 2026.
The reclassification was conducted under Regulation 31A of SEBI Listin